
Novartis
NVSEF | OTC
$134.20
-$6.73 (-4.78%)
At close: Oct 2, 2026, 3:14 PM ET
Novartis Company Profile
Company profile explainedCompany Profile
Novartis AG, a global pharmaceutical enterprise established in 1996 and based in Basel, Switzerland, is engaged in the entire lifecycle of healthcare products, from research and development to manufacturing and worldwide commercialization. The company's operations are divided into two main divisions: Innovative Medicines and Sandoz. The Innovative Medicines segment is dedicated to providing advanced prescription medications to both patients and healthcare professionals. Its extensive product portfolio covers a wide range of therapeutic areas, including ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory conditions, cardiovascular health, renal diseases, and metabolism. Conversely, the Sandoz segment specializes in a comprehensive array of generic and biosimilar products. This involves the creation, production, and distribution of finished dosage form medicines, as well as active ingredients and small molecule pharmaceuticals for external partners. Sandoz also supplies generic drugs for retail, anti-infectives, and crucial active pharmaceutical ingredients (APIs) and intermediates, particularly antibiotics. Additionally, this division is involved in developing protein-based and other biotechnology products, such as biosimilars, and offers biotechnology manufacturing services. Novartis AG also pursues strategic collaborations. It has a licensing and collaboration agreement with Alnylam Pharmaceuticals concerning the development, production, and commercialization of inclisiran. Moreover, the company maintains a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in treating head and neck squamous cell carcinoma patients.
Key Executives
| Name | Position |
|---|---|
| Vasant Narasimhan | Chief Executive Officer |
| Mukul Mehta | Chief Financial Officer |
| Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research |
| Karen L. Hale | Chief Legal & Compliance Officer |
| Patrick Horber | President of International |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Robert Kowalski | Chief People & Organization Officer |
| Sloan Simpson | Global Head of Investor Relations |
| Steffen Lang | President of Operations |
| Victor Bulto | President of US |
Novartis

| Country | Switzerland |
| IPO Date | Apr 26, 2010 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,267 |
| CEO | Vasant Narasimhan |
Stock Details
| Ticker Symbol | NVSEF |
| Exchange | OTC |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | n/a |
| ISIN Number | CH0012005267 |
| SIC Code | 2834 |
Recent News
- 4 months ago / seekingalpha.comHow To Build A $50,000 Dividend Portfolio In Today's Market
Add to Watchlist
Select watchlists to add or remove NVSEF